As part of a prospective study evaluating ART deferral among newly diagnosed HIV infected individuals at 4 participating local primary healthcare (PHC) clinics in Johannesburg, South Africa,[20] a baseline cross-sectional survey was conducted among 652 participants from October 2017 to August 2018. Eligibility requirements for the study included being newly diagnosed of HIV on the day of study enrolment, being 18 years or older, not previously initiated on ART, not pregnant, not planning to get treatment elsewhere, physically and psychologically well enough to participate, and willing to provide informed consent. All participants provided written informed consent to participate in the study. Consent forms translated from English into Sotho and Zulu and administered in the participant's preferred language (English, Sotho or Zulu). Of the patients that were approached to participate in the main study (n = 703), 1.9% refused, while 5.4% were not eligible (Fig. (Fig.1).1). Further, a total of 123/652 (18.9%) of study participants enrolled in the main study were found to be known HIV positive patients but presented for testing as new patients. The current analysis includes cross-sectional data collected using a baseline questionnaire at study enrolment among 529 eligible participants.

Patient recruitment, eligibility, and enrolment of adults (≥18 years) at 4 clinics in Johannesburg.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.